Inclusion criteria were EF@ % , a mitral E-wave velocity/mitral annular velocity ratio ( E/E ' ) > @ or N-terminal pro-B-type natriuretic peptide ( NT-proBNP ) concentration > @ pg/ml , a left ventricular end-diastolic pressure ( LVEDP ) @ mm Hg , and time-constant of relaxation ( tau ) @ ms. Patients were randomized to ranolazine ( n = @ ) or placebo ( n = @ ) .